Imaging informatics upstart gets FDA nod for oncology screening software

HealthMyne has secured 510(k) clearance for its analytics software package that's designed to offer radiologists information in oncology imaging studies. The software from the Madison, WI-based company is designed to work as part of an Epic electronic health record and offer tracking of specific nodules or tumors over time. The software is used to analyze its relative size and location.

Cancer screening programs can use the HealthMyne software to evaluate nodules in, for example, suspected lung cancer patients. Nodule growth can be an indicator of malignancy and suggest further scrutiny.

"By automatically delineating the boundaries of a lung nodule (or tumor), our software can make other sophisticated measurements within those boundaries--such as quantitatively describing important properties like size, shape, and texture," said HealthMyne CTO Roger Chylla in a statement. "Physicians can examine these properties to make critical judgements about a patient's prognosis, follow-up schedule, or how to best treat them."

HealthMyne was founded in 2013 and last year got a $4.5 million Series A financing led by a pair of Madison venture firms: Venture Investors and 4490 Ventures. The founders see the company as part of a larger movement toward evidence-based medicine that will benefit from fine-tuning analyses for clinical imaging and oncology.

The first product is specifically aimed at helping physicians better detect and diagnose lung nodules as part of a comprehensive low-dose CT lung screening program.

"There's been a lot of attention directed toward personalized health and evidence-based medicine, but we feel confident that we are in the best position to turn that vision into reality for clinical imaging and oncology," said HealthMyne chairman Rock Mackie last March when HealthMyne got its Series A. He has led medical imaging players including TomoTherapy, based on an image-guided radiation treatment technology. It subsequently sold to Accuray in 2011 for about $277 million.

- here is the announcement

Suggested Articles

BD will begin offering a point-of-care COVID-19 antibody assay, which operates like a combination of a blood glucose test and a home pregnancy test.

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.